Abstract
Ecto-nucleotide pyrophosphatase/phosphodiesterases (NPPs) hydrolyse nucleotide triphosphates to the corresponding nucleotide monophosphates and the mineralisation inhibitor, pyrophosphate (PPi). This study examined the role of NPP1 in osteocytes, osteoclasts and cortical bone, using a mouse model lacking NPP1 (Enpp1−/−). We used microcomputed tomography (μCT) to investigate how NPP1 deletion affects cortical bone structure; excised humerus bones from 8, 15 and 22-week old mice were scanned at 0.9 μm. Although no changes were evident in the cortical bone of 8-week old Enpp1−/− mice, significant differences were observed in older animals. Cortical bone volume was decreased 28% in 22-week Enpp1−/− mice, whilst cortical porosity was reduced 30% and 60% at 15 and 22-weeks, respectively. This was accompanied by up to a 15% decrease in closed pore diameter and a 55% reduction in the number of pores. Cortical thickness was reduced up to 35% in 15 and 22-week Enpp1−/− animals and the endosteal diameter was increased up to 23%. Thus, the cortical bone from Enpp1−/− mice was thinner and less porous, with a larger marrow space. Scanning electron microscopy (SEM) revealed a decrease in the size and number of blood vessel channels in the cortical bone as well as a 40% reduction in the mean plan area of osteocyte lacunae. We noted that the number of viable osteocytes isolated from the long bones of Enpp1−/− mice was decreased ≤ 50%. In contrast, osteoclast formation and resorptive activity were unaffected by NPP1 deletion. μCT and histological analysis of Enpp1−/− mice also revealed calcification of the joints and vertebrae as well as soft tissues including the whisker follicles, ear pinna and trachea. This calcification worsened as the animals aged. Together, these data highlight the key role of NPP1 in regulating calcification of both soft and skeletal tissues.
Keywords: NPP1, Osteocytes, Osteoclasts, Soft tissue mineralisation, Pyrophosphate
Highlights
-
•
We examine the role of NPP1 in osteocytes, osteoclasts and cortical bone.
-
•
Osteocyte lacunae are reduced in size and number in NPP1 knockout mice.
-
•
Sclerostin levels are increased in NPP1 knockout mice.
-
•
Osteoclast formation and resorptive activity are unaffected by NPP1 deletion.
-
•
Mice lacking NPP1 display widespread calcification of collagen rich soft tissues.
Introduction
The ability of pyrophosphate (PPi) to inhibit mineralisation was first identified in the 1960s by Fleisch and colleagues [1]. It is now accepted that the ratio of PPi to phosphate (Pi) within the bone microenvironment is a fundamental regulator of the level of mineralisation [2], [3]. PPi can be generated from nucleotide triphosphates (such as ATP or UTP) by the actions of ecto-nucleotidase pyrophosphatase/phosphodiesterases (NPPs). These transmembrane proteins display widespread expression and are highly conserved between species. Osteoblasts express at least 3 members of the NPP family (NPP1, 2, 3) [4], [5], [6], and of these, NPP1 (previously called plasma cell membrane glycoprotein 1 or PC-1), is thought to be the most important NPP in PPi generation. Tissue-nonspecific alkaline phosphatase (TNAP) is the key enzyme involved in PPi breakdown [4]. Previous work has shown that the opposing actions of NPP1 and TNAP are critical in determining the extracellular Pi/PPi ratio and, thus, the level of skeletal mineralisation [5]. Furthermore, the inhibitory actions of ATP and UTP on bone mineralisation appear to be partly mediated via the actions of NPP1 [6], [7], [8].
NPP1 expression has now been demonstrated in a wide range of tissues and cell types including the heart, kidney, vascular smooth muscle cells and chondrocytes [9], [10], [11], [12]. In addition to its role in regulating mineralisation, NPP1 is also thought to be involved in glucose homeostasis and insulin signalling [13], [14], [15]. Mutations in the gene encoding NPP1 (Enpp1) have been associated with a rare autosomal recessive disease generalised arterial calcification of infancy (GACI) [16]. Sufferers of this condition usually die in infancy because of substantial vascular calcification.
The important role of NPP1 in the regulation of tissue mineralisation has been highlighted by two different mouse models; the naturally occurring NPP1 ‘knockout’ termed the tip-toe walking (ttw/ttw) mouse and the genetically altered NPP1 knockout (Enpp1−/−). The ttw/ttw model displays ossification of the spinal ligaments, peripheral joint hyperstosis and calcification of articular cartilage [17]. The phenotype of ttw/ttw mice also has similarities to the human disease ‘Ossification of the posterior longitudinal ligament of the spine’ (OPLL). The Enpp1−/− model displays a number of defects related to reduced PPi production, including calcification of the aorta, kidney, spine, joints and cartilage [4], [18], [19], [20], [21]. Suprisingly, given the reduction in extracellular PPi levels, Enpp1−/− mice display reduced trabecular and cortical bone in the long bones and decreased bone strength [20]. These animals also have increased FGF-23 levels [20] and decreased osteopontin levels [19]. Earlier work also showed an increased number of osteoclasts on the ex vivo bone surfaces of Enpp1−/− mice [20]. This was associated with an increase in the blood serum concentration of the bone resorption marker, C-terminal telopeptides of type I collagen (CTx), and suggests increased osteoclast activity in Enpp1−/− animals [20].
Osteocytes, the most abundant cell type in bone [22], reside within lacunae surrounded by mineralised matrix. Extensive dendritic processes extend through canaliculi to form a highly connected communication network between osteocytes and the other cells on the bone surface. Soluble factors released by osteocytes regulate osteoblast and osteoclast function thereby providing a mechanism to control bone remodelling [23], [24]. Osteocytes also play a role in phosphate metabolism, calcium availability and are the primary mechanosensory cell within bone [24]. The viability of osteocytes plays a significant role in maintaining bone homeostasis as cell death has been associated with pathological conditions such as osteoporosis and osteoarthritis [24], [25].
Mature osteoblasts express high levels of NPP1 [26] and, consequently, most studies to date have focused on the role of this enzyme in bone mineralisation and/or osteoblast differentiation [20], [27], [28]. The aim of this investigation was to determine whether the actions of NPP1 affect osteocyte function and cortical bone structure. The ability of NPP1 to influence osteoclast formation and bone resorption was also examined.
Methods
Reagents
All tissue culture and molecular biology reagents were purchased from Life Technologies (Paisley, UK) unless stated otherwise. Chemical reagents were purchased from Sigma Aldrich (Poole, Dorset, UK).
Enpp1−/− mice
The generation and characterisation of Enpp1−/− mice, which are on a 129Sv/TerJ genetic background, have previously been described [29]. All animal experiments were approved by UCL's animal users committee and animals were maintained in accordance with UK Home Office guidelines for the care and use of laboratory animals.
Microcomputed tomographic (μCT) analysis of Enpp1−/− mice
The humerus, head, knees, spine, trachea and paws were isolated from 8, 15 and 22-week old Enpp1−/− and wild-type (Enpp1+/+) mice and fixed in 10% neutral buffered formalin for 24 h. Samples were then washed in phosphate buffered saline and stored in 70% ethanol until scanning. All scans were performed using a Skyscan 1172 μCT scanner (Bruker, Kontich, Belgium). The humerus bones were scanned at 50 kV and 20 μA, using a 0.25 mm aluminium filter and a resolution of 0.9 μm. All other tissues were scanned using an image pixel size of between 5–10 μm and a 0.5 mm aluminium filter. To analyse the cortical bone of the humerus, a 0.25 mm region of interest was selected 0.5 mm below the deltoid tuberosity. The images were reconstructed using the Skyscan Nrecon software and analysed using the Skyscan CTan program.
Histology
Histological analysis was performed on the trachea, ears and whisker follicles of Enpp1+/+ and Enpp1−/− mice. Tissues were fixed in 10% neutral buffered formalin and infiltrated with paraffin wax using an automated tissue processor (Leica Microsystems, Wetzlar, Germany). Samples were manually set within paraffin wax blocks before being cut into 3 μm sections and mounted onto slides. Before staining, the samples were de-paraffinised using xylene, then rehydrated through a series of decreasing ethanol solutions and finally water. Slides were stained for calcium using alizarin red (1% w/v), washed three times in deionised water and counter-stained with fast green (1% w/v). After staining, the samples were covered with a glass cover slip and imaged using a Nanozoomer slide imaging system (Hamamatsu, Hamamatsu City, Japan).
Scanning electron microscopy
The femurs were dissected from 15 and 22-week old Enpp1+/+ and Enpp1−/− mice and cut along the longitudinal axis using a Buehler Isomet saw (Düsseldorf, Germany). The bone marrow, and any remaining soft tissue, was digested away in a 6% Tergazyme solution, pH 8.0 (Alconox, White Plains, NY, USA), for three weeks. The bones were dehydrated (50% ethanol, 2 h; 70% ethanol, 2 h; 100% ethanol, overnight) before being left to air dry. Images from the 15 and 22-week old animals were taken using a Zeiss EVO MA10 scanning electron microscope (SEM) (Zeiss, Oberkochen, Germany) at Queen Mary, University of London or a JEOL 7401 SEM (JEOL, Tokyo, Japan) at UCL, respectively. Analysis of SEM images (Image J, NIH, USA) was used to determine the number and size of blood vessel channels and osteocyte lacunae. A 2.0 mm region of interest located 4 mm below the growth plate on the endosteal surface of the cortical bone was selected for image analysis.
Mouse osteocyte-like and osteoblast cell culture
Primary mouse osteocytes were obtained from the long bones of 15-week old Enpp1+/+ and Enpp1−/− using the methods described by Stern and colleagues [30]. Following isolation, cells were seeded onto collagen coated 6-well trays at a density of 2 × 105 cells per well in αMEM. Half media changes were performed on every third day; the cells were used for experimental procedures on day 7. The number of cells present was counted manually using light microscopy.
Mouse osteoblasts were obtained from the calvaria of neonatal Enpp1+/+ and Enpp1−/− mice by trypsin/collagenase digestion as described previously [31]. Cells were cultured for up to 28 days in αMEM supplemented with 50 μg/ml ascorbate and 2 mM β-glycerophosphate.
Total RNA extraction and complimentary DNA strand synthesis
Osteoclasts were cultured on dentine discs for up to 10 days before RNA was extracted using TRIzol® reagent according to the manufacturer's instructions. RNA was extracted from osteoblasts and osteocytes on day 21 and day 7 of culture, respectively. Before first stand complementary DNA (cDNA) synthesis extracted RNA was treated with RNase-free DNase I (35 U/ml) (Promega, Southampton, UK) for 30 min at 37 °C. The reaction was terminated by heat inactivation at 65 °C for 10 min. Total RNA was quantified spectrophotometrically by measuring absorbance at 260 nm. For each sample, 0.5 μg of DNase-treated total RNA was used as a template for first strand cDNA synthesis in a 20 μl reaction also containing 0.5 μg oligo dT, 3 mM MgCl2, 0.5 mM dNTPs, 20 U recombinant RNasin® ribonuclease inhibitor, ImProm-II® 5 × reaction buffer and 200 U ImProm-II reverse transcriptase. The reaction mix was annealed for 5 min at 25 °C, followed by extension at 42 °C for 60 min and inactivation at 70 °C for 15 min. cDNA was stored at − 20 °C until amplification by RT-PCR or qRT-PCR.
RT-PCR
Osteoclast and osteocyte-derived cDNA was amplified by PCR in 25 μl reactions containing ~ 0.5 μg cDNA, 0.2 mM dNTP, 1.5 mM MgCl2, 0.2 μM of both sense and anti-sense primer, 1 U Taq DNA polymerase in thermophilic DNA polymerase 10 × buffer. PCR was performed according to the manufacturer's instructions for between 30–40 cycles of amplification. Denaturation at 95 °C for 30 s, annealing for 30 s at a primer specific temperature and extension at 72 °C for 45 s took place within each cycle, followed by reaction termination at 72 °C for 5 min. For analysis, PCR products were loaded on to 1% agarose gels containing 0.3 μg/ml ethidium bromide. Gels were run at ~ 80 mA and the DNA position visualised by exposure to UV light. To account for differences in original cell number and cDNA quality, osteoclast samples were normalised against mRNA for GAPDH. All reactions were carried out in triplicate using cDNAs derived from 3 different osteoclast/osteocyte cultures. Primer sequences are shown in Table 1. The RT-PCR positive control used samples from mouse brain.
Table 1 Primer sequences for RT-PCR.
Mus musculus gene | Sense 5′–3′ | Anti-sense 5′–3′ |
---|---|---|
GAPDH | CTCACTCAAGATTGTCAGCA | GTCATCATACTTGGCAGGTT |
Enpp1 | ACAGCTTAATCTGACCACAG | GATCCTGGTACAGACAGTTG |
Enpp2 | GTATGACCCTGTCTTTGATG | GAAAGCCACTGAAGGATAGT |
Enpp3 | CTGCTGACTGTGGTTTTACT | CTGTGGTAAAGGAGACAGTG |
NTPdase1 | CTTTGGCGCTTTGGATCTCG | TCTGGTGGCACTGTTCGTAG |
NTPdase2 | CTGGAGGCAGTGACACAGAC | TGGGTGGAGTAGCCCTTTGG |
NTPdase3 | GTGAGCATTGTGGTACTTGT | TGACCACTCCTGTGTTATTC |
ANK | CAGTTTCCTGGTGGGATGTG | TTGATGTGGGCTGAGGTG |
GAPDH = glyceraldehyde-3-phosphate dehydrogenase, Enpp = ecto-nucleotide pyrophosphatase/phosphodiesterase, NTPdase = ecto-nucleoside triphosphate diphosphohydrolase, ANK = progressive ankylosis gene.
Quantitative real-time PCR (qRT-PCR)
Osteoblast and osteocyte cDNAs were amplified using specific QuantiTect primers (β-actin, sclerostin) and QuantiTect SYBR® Green (Qiagen Ltd, Crawley UK). qRT-PCR (Chromo4, Biorad Laboratories Ltd, Hemel Hempstead, UK) was performed according to manufacturer's instructions with an initial activation step (94 °C for 15 min) followed by 40 cycles of denaturation (95 °C for 10 s) and detection (60 °C for 30 s). Gene expression was investigated in osteocytes and mature, bone forming osteoblasts. Data was analysed using the Pfaffl method [32] and is shown as relative expression of sclerostin in Enpp1+/+ and Enpp1−/− cells. All reactions were carried out in triplicate using RNAs derived from 3 different osteoblast/osteocyte cultures.
Measurement of serum sclerostin
Blood was collected from 8, 15 and 22-week old Enpp1−/− and Enpp1+/+ mice by cardiac puncture immediately after termination. Following clotting, samples were centrifuged at 500 g and the serum was retained and frozen until analysis. Serum sclerostin was measured using a commercially available ELISA kit (R&D systems, Abingdon, UK), as per the manufacturer's instructions. It is unknown which of the many forms of secreted sclerostin [33] are detected by this kit.
Measurement of extracellular ATP
Prior to measurement of ATP levels, culture medium was removed, cell layers were washed and cells were incubated with serum-free DMEM (1 ml/well) for 1 h. Extracellular ATP release was measured luminetrically using the luciferin–luciferase assay as previously reported [34]. Cell number was determined using the CytoTox 96® non-radioactive cytotoxicity assay (Promega, Southampton, UK).
Osteoclast formation assay
Osteoclasts were generated from the bone marrow of 8 or 15-week old Enpp1+/+ or Enpp1−/− mice as previously reported [35]. Briefly, cells were plated onto 5 mm diameter dentine discs (106 cells) in αMEM supplemented with 100 nM PGE2, 200 ng/ml M-CSF and 3 ng/ml receptor activator of nuclear factor ΚB (RANKL; R&D Systems Europe Ltd, Abingdon, UK). After 24 h, discs containing adherent osteoclast precursors were transferred to 6 well trays (4 discs/well in 4 ml medium) for a further 6 days at 37 °C in 5% CO2/95% atmospheric air. Culture medium was acidified to pH ~ 7.0 by the addition 10 meq/l H+ (as HCL) on day 7 to activate osteoclastic resorption of dentine [35], [36], [37], [38]. Culture medium pH, pCO2 and PO2 were monitored throughout using a blood gas analyser (ABL 705, Radiometer, Copenhagen, Denmark). Osteoclasts were fixed in 2% glutaraldehyde and stained to demonstrate tartrate-resistant acid phosphatase (TRAP). Osteoclasts were defined as TRAP-positive cells with 2 or more nuclei and/or clear evidence of resorption pit formation. Osteoclast number and the plan surface area of resorption pits were measured as described previously [35].
Total cellular NPP activity measurement
The assay used to measure total cellular NPP activity was based on the method originally described by Razzell and Khorana [39]. Briefly, cells were lysed in a buffer containing 1% triton × 100 in a 0.2 M Tris base with 1.6 mM MgCl2, pH 8.1. Following centrifugation at 500 g the NPP activity of collected supernatants was measured using 5 mM p-nitrophenyl-thymidine 5′-monophosphate as substrate. Total protein concentration in cell l lysates was measured using the Bradford method.
Statistics
Statistical comparisons were made using a t-test or one-way analysis of variance (ANOVA) and adjusted using the Bonferroni method [40], [41]. Calculations were performed using In Stat 3 (GraphPad, San Diego, CA). All data are presented as means ± SEM for between 6–12 replicates. Results are representative of experiments performed at least three times, unless otherwise stated.
Results
Ectopic mineralisation in Enpp1−/− mice
Previous studies have reported aberrant mineral deposition in Enpp1−/− mice [4], [20], [27]. Here, we used μCT imaging to visualise this ectopic mineralisation at high resolution. Enpp1−/− mice displayed mineralisation between the vertebrae (Fig. 1A) and of the ligaments within the knee joint (Fig. 1B). Within the paws, there was mineralisation of the joint capsules and the metatarsals and phalanges were partially fused together (Fig. 1C).
Interestingly, we also observed mineral deposits in several collagen rich soft tissues including the whisker follicles, trachea and ear pinna of Enpp1−/− mice (Figs. 1D–H). The mineralisation of the whisker follicles was sub-dermal, not visible to the naked eye, nor easily detectable by touch. To ensure that the mineralisation of the vibrissae observed by μCT was not an artefact of the scanning, histology was performed on the whisker follicles of Enpp1+/+ and Enpp1−/− mice. Alizarin red staining showed that the collagenous sheath surrounding the whisker follicles in Enpp1−/− mice contained calcium mineral. No other mineralisation was detected in this tissue and the smaller hair follicles, which are not surrounded by collagen, were not mineralised (Fig. 1E). μCT analysis and histology also demonstrated mineralisation within the cartilage rings of the trachea (Figs. 1F & G) and the ear pinna of Enpp1−/− mice (Figs. 1D & H).
In all cases, soft tissue mineralisation was evident from 8 weeks and worsened with age; the representative images shown are from 15 (Figs. 1A–C) and 22-week old (Figs. 1D–H) animals.
Enpp1−/− mice have thinner and less porous cortical bone with a bigger bone marrow cavity
This study used high resolution μCT to examine in detail how NPP1 deletion affects cortical bone structure. Representative images of the cortical bone at 8, 15 and 22-weeks are shown in Fig. 2A. No differences in any of the cortical bone parameters measured were observed in the 8-week animals (Fig. 2). Cortical bone volume was decreased up to 28% in Enpp1−/− mice (Fig. 2B). This was accompanied by 16% and 35% reduction in cortical thickness in 15 and 22-week old Enpp1−/− animals, respectively (Fig. 2C). Enpp1+/+ mice displayed increasing cortical thickness with age (57% higher at 22-weeks compared to 8-weeks); this age-related increase in cortical thickness did not occur in Enpp1−/− mice (Fig. 2C). The endosteal diameter, which represents the diameter of the bone marrow cavity, was increased up to 23% in Enpp1−/− mice (Fig. 2D). The periosteal diameter was unchanged by NPP1 deletion (Fig. 2E).
Total porosity represents all the space within the cortical bone that is not filled by bone mineral e.g. blood vessels channels or osteocyte lacunae. We found that total porosity was decreased 30% and 60% in 15 and 22-week old Enpp1−/− mice, respectively (Figs. 2A & F). The total volume of closed pores, which equates to the spaces totally enclosed by mineral, was reduced up to 55% in Enpp1−/− animals (Fig. 2G). The number of closed pores was decreased 40% and 59% at 15 and 22-weeks, respectively (Fig. 2H). Pore diameter was reduced up to 15% in Enpp1−/− mice (Fig. 2I).
Differences in the total x-ray attenuation of the μCT scans can indicate whether a tissue is hypermineralised (i.e. the matrix is overly mineralised). Analysis of the x-ray attenuation within the cortical bone revealed no differences between the Enpp1+/+ and Enpp1−/− mice at any age (not shown).
Reduced size of vascular channels and osteocyte lacunae in Enpp1−/− mice
Low power SEM analysis of the femur showed that the number and size of the vascular channels on the endosteal surface of the cortical bone was reduced up to 50% and 70%, respectively in Enpp1−/− mice (Figs. 3A–C & E–F). SEM at higher power was then used to visualise osteocyte lacunae on cortical bone surfaces (Figs. 3B & D). Quantification of SEM images showed that the lacunae diameter was reduced up to 25% in Enpp1−/− mice (Fig. 3F). The plan surface area of the lacunae was decreased 35% and 39% in 15 and 22-week old Enpp1−/− animals (Fig. 3G). It was also noted that in Enpp1+/+ animals there was a reduction in the size of the osteocyte lacunae as the animals aged (Fig. 3G).
Expression of NPP1 by mouse osteocyte-like cells
Mouse osteocyte-like cells extracted from the long bones of 15-week old Enpp1−/− and Enpp1+/+ mice displayed the characteristic dendritic processes of osteocytes (Figs. 4A & B). RT-PCR showed that Enpp1+/+ osteocyte-like cells express mRNA for the osteocyte specific gene, DMP1, and for Enpp1 (Fig. 4C).
Increased sclerostin levels in Enpp1−/− mice
Sclerostin mRNA expression was increased ~ 9-fold in osteocytes (Fig. 4D) and ~ 16-fold in mature, bone forming osteoblasts (Fig. 4E) derived from Enpp1−/− mice. No differences in the serum concentration of sclerostin were seen in 8-week old animals. However, sclerostin levels were increased 75% and 52% in 15 and 22-week old Enpp1−/− mice, respectively (Fig. 4F). In Enpp1+/+ animals, ageing was associated with a 62% reduction in serum sclerostin levels; this decrease was not seen in Enpp1−/− mice.
Reduced number and ATP release in cultures of Enpp1−/− osteocyte-like cells
Osteocyte-like cells extracted from the bones of Enpp1−/− and Enpp1+/+ mice were cultured for 7 days. The number of osteocyte-like cells was reduced by 48% in Enpp1−/− cultures (Fig. 4G). Constitutive ATP release from Enpp1−/− osteocyte-like cells into the culture medium was decreased by 80% compared to Enpp1+/+ cells (Fig. 4H).
Osteoclasts expressed mRNA for NPP1 and other ecto-nucleotidases
RT-PCR analysis was performed on osteoclast precursors (day 3), early osteoclasts (day 6), mature osteoclasts (day 8) and mature resorbing osteoclasts (day 10) to investigate the expression of ecto-nucleotides in these cells. We found that osteoclasts express mRNAs for Enpp1, Enpp3, NTPdase1, NTPdase3 and the transport protein, Ank, from day 6 onwards; mRNA expression of Enpp2 and NTPdase 2 was not detected (Fig. 5A). Enpp1 mRNA expression increased as osteoclastogenesis progressed with peak levels in mature, resorbing cells. In contrast, mRNA levels of Enpp3 and NTPdase 3 were lower in mature osteoclasts. Expression of Ank and NTPdase 1 mRNA remained relatively constant (Fig. 5A).
Osteoclasts display NPP activity
Total cellular NPP activity was measured in osteoclasts at all stages of differentiation. We found that osteoclasts exhibited functional NPP activity, which decreased as osteoclastogenesis progressed (Fig. 5B) Enpp1−/− osteoclasts displayed up to a 70% reduction in total NPP activity (Fig. 5B).
Osteoclast formation and activity is unaffected by NPP1 deletion
Osteoclasts were generated from 8 and 15-week old Enpp1−/− and Enpp1+/+ mice and cultured on dentine discs for 9 days. Representative transmitted and reflective light microscopy images of the osteoclasts formed from these animals are shown in Fig. 5C. No differences in osteoclast formation or resorptive activity were seen in Enpp1−/− osteoclasts from 8-week (Fig. 5D) and 15-week old (not shown) animals.
Discussion
The role of NPP1 in tissue mineralisation has been widely studied using rodent models. In particular, the global ablation of Enpp1−/− function has provided considerable information about the actions of NPP1 in different tissues (see review by Mackenzie et al. 2012 [18]). Within bone, the effects of NPP1 on osteoblast differentiation and function have been well documented [20], [27], [28], yet information regarding its role in osteocytes and osteoclasts is limited. This study demonstrated for the first time that NPP1 is expressed by both cell types. Using Enpp1−/− mice we identified a key role for NPP1 in maintaining the size of osteocyte lacunae.
Earlier investigations reported that Enpp1−/− mice exhibit aberrant mineralisation of the aorta, joints, spine and cartilage [4], [19], [20], [21]. During our μCT analysis of these mice we also observed extensive ectopic calcification in the above tissues. We additionally saw mineralisation in several soft tissues where it had not previously been detected. The whisker follicles, ear pinna and trachea all contain type I or type II collagen which could act as a site for mineral deposition. The mineralisation of these tissues in knockout mice suggests that, under normal conditions, production of PPi from ATP by NPP1 is important in preventing calcification.
The initial studies of Enpp1−/− mice showed that these animals had reduced bone mineral content (BMC) in the long bones [27]. Subsequent, more detailed analysis by Mackenzie et al. [20] showed that Enpp1−/− mice display reduced trabecular bone volume, thickness and number as well as decreased cortical thickness and porosity. In agreement, we also observed age-related decreases in cortical bone volume, thickness and porosity. Additionally, we found that whilst the periosteal diameter was unchanged the endosteal diameter was increased making the cortical bone in Enpp1−/− mice thinner and less porous with a larger marrow space. Taken together, these studies show that the reduced BMC of the long bones originally identified by Anderson et al. [27] involves decreased bone in both the trabecular and cortical compartments.
Cortical porosity, as measured using μCT, is a measurement of all of the spaces within the bone including vascular channels, osteocyte lacunae or microcracks. The μCT analysis performed by Mackenzie et al. [20] used a resolution of 5 μm, which although adequate for determining overall changes in cortical bone volume and porosity, was not sufficient to provide detailed information about the osteocyte lacunae. Here, we used higher resolution μCT (0.9 μm) and SEM to examine whether the changes in cortical porosity could reflect alterations in the size of osteocyte lacunae in Enpp1−/− mice. We found that the number, volume and diameter of the closed pores were reduced in Enpp1−/− animals; this was accompanied by a decrease in the number of osteocytes isolated from the long bones. Subsequent analysis of SEM images also showed a reduction in lacunar diameter and area. The most likely explanation for the decreased osteocyte lacunar size in Enpp1−/− mice is a localised increase in the amount of matrix mineralisation, which could have a negative impact on osteocyte function and survival. Further studies will be needed to assess the effect of NPP1 deletion on osteocyte numbers in situ and on the fine canaliculae that interconnect these cells. Previously, increased mineralisation of the osteocyte lacunae has been linked with ageing [42], osteoporosis and osteoarthritis [25].
Cultured MLO-Y4 osteocyte-like cells have been reported to release ATP constitutively [43], [44]. The present work shows that primary osteocyte-like cells from mouse long bones also release ATP and, moreover, express mRNA for NPP1. This suggests that osteocytes are capable of hydrolysing ATP to generate the mineralisation inhibitor, PPi, in their extracellular environment. Earlier work has shown that extracellular PPi levels are reduced in the culture medium of Enpp1−/− osteoblasts [19]. Therefore, it is possible that the decreased lacunar size in Enpp1−/− mice is due to increased mineralisation that is the result, at least in part, of a lower concentration of ATP-derived PPi.
Despite exhibiting mineralisation of soft tissues and osteocyte lacunae, Enpp1−/− mice display a decreased trabecular and cortical bone volume [20]. It has been suggested that the reduced bone seen in Enpp1−/− animals occurs because there is insufficient PPi for TNAP to generate the Pi needed for normal bone formation [18]. However, the reduction in the size and number of the vascular channels within the cortical bone of Enpp1−/− mice could provide a further pathophysiological mechanism for the decreased bone mass in these animals. A decreased vascular supply to the bones, perhaps exacerbated by the aortic calcification previously described in Enpp1−/− mice [18], [45], would result in hypoxia and acidosis, which are well known to increase osteoclast formation and resorption [36], [37], whilst also inhibiting bone mineralisation [46], [47], [48]. In support of this notion, we observed prominent fields of resorption pits on the endosteal surfaces of Enpp1−/− bones and Enpp1−/− mice have increased levels of potassium ions, which can be a marker of acidosis, within the blood [20].
Sclerostin, which is secreted by osteocytes, inhibits Wnt signalling and negatively regulates bone formation [49]. We found that serum sclerostin levels were higher in Enpp1−/− mice and that sclerostin mRNA expression was strongly increased in Enpp1−/− osteocyte-like cells and mature, bone forming osteoblasts. Previous studies have shown that mechanical loading regulates sclerostin expression, with increased levels in unloaded bones [50], [51], [52], [53], [54]. Enpp1−/− mice display an unusual walking gait [17], [29], muscle damage [20] and mineralisation of the spine, knees and toes, which combined are likely to affect the mechanical loading of their bones. Thus, the elevated blood sclerostin in Enpp1−/− mice may be due not only to constitutively higher production by bone cells but also to decreased mechanical loading. These factors are consistent with the reduced bone mass observed in these animals. Enpp1−/− mice also display increased expression of FGF23, an osteocyte-derived phosphaturic hormone that can inhibit bone mineralisation [20]. Recently it was reported that sclerostin can indirectly regulate FGF23 expression since sclerostin knockout mice display reduced levels of serum FGF23 [55]. Therefore, the increased FGF23 levels in Enpp1−/− mice could be a consequence of the higher sclerostin levels.
This study demonstrated for the first time that osteoclasts express several ecto-nucleotidases including NPP1. Osteoclasts also exhibit significant NPP activity making them capable of contributing to extracellular PPi levels. A significant portion of this NPP activity was due to NPP1 suggesting that, like osteoblasts, this is the pre-eminent NPP in osteoclasts. μCT analysis showed that whilst the endosteal diameter was increased in Enpp1−/− mice, the periosteal diameter was unchanged. This increase in the endosteal/periosteal ratio is indicative of increased osteoclast activity in the bone. In agreement, Mackenzie and colleagues saw histological and biochemical evidence of increased in vivo osteoclast activity in Enpp1−/− mice [20]. Our current study found no differences in osteoclast formation and activity when Enpp1−/− osteoclasts were generated in vitro from bone marrow precursors. However, the SEM images shown in Fig. 3 do show an apparent increase in bone resorption on the endosteal surface of the cortical bone from Enpp1−/− mice. The discrepancy between the in vitro and in vivo data suggests that any effects of NPP1 deletion on osteoclasts are mediated by other cells.
In summary, the work presented here shows that NPP1 plays a key role in regulating soft tissue and skeletal mineralisation. The ectopic mineralisation observed in several collagen rich soft tissues suggests that NPP1 expression is more widespread than previously reported. Our findings also suggest that expression of NPP1by osteocytes may be important in preventing the over-mineralisation of their lacunae (which could potentially compromise osteocyte function or survival). Finally, since age-related pathological calcification is a common in humans, the rapidly worsening phenotype of Enpp1−/− mice may, in some respects, represent a useful model of accelerated ageing.
Acknowledgments
The authors are grateful for funding from Arthritis Research UK (Career Developmental Fellowship, IRO), (Grant no.19205) and the Biotechnology and Biological Sciences Research Council (BBSRC; Institute Strategic Programme Grant and Institute Career Path Fellowship, VEM)
Edited by: Mark Johnson
References
- 1.Fleisch H., Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol. 1962;203:671–675. doi: 10.1152/ajplegacy.1962.203.4.671. [DOI] [PubMed] [Google Scholar]
- 2.Felix R., Fleisch H. Pyrophosphatase and ATPase of isolated cartilage matrix vesicles. Calcif Tissue Res. 1976;22:1–7. doi: 10.1007/BF02010340. [DOI] [PubMed] [Google Scholar]
- 3.Kornak U. Animal models with pathological mineralization phenotypes. Joint Bone Spine. 2011;78:561–567. doi: 10.1016/j.jbspin.2011.03.020. [DOI] [PubMed] [Google Scholar]
- 4.Hessle L., Johnson K.A., Anderson H.C., Narisawa S., Sali A., Goding J.W. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002;99:9445–9449. doi: 10.1073/pnas.142063399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Johnson K.A., Hessle L., Vaingankar S., Wennberg C., Mauro S., Narisawa S. Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol. 2000;279:1365–1377. doi: 10.1152/ajpregu.2000.279.4.R1365. [DOI] [PubMed] [Google Scholar]
- 6.Orriss I.R., Utting J.C., Brandao-Burch A., Colston K., Grubb B.R., Burnstock G. Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology. 2007;148:4208–4216. doi: 10.1210/en.2007-0066. [DOI] [PubMed] [Google Scholar]
- 7.Orriss I.R., Key M.L., Brandao-Burch A., Patel J.J., Burnstock G., Arnett T.R. The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: the role of P2X receptors. Bone. 2012;51:389–400. doi: 10.1016/j.bone.2012.06.013. [DOI] [PubMed] [Google Scholar]
- 8.Orriss I.R., Key M.L., Hajjawi M.O., Arnett T.R. Extracellular ATP released by osteoblasts is a key local inhibitor of bone mineralisation. PLoS One. 2013;8:e69057. doi: 10.1371/journal.pone.0069057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Johnson K., Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage. Front Biosci. 2005;10:988–997. doi: 10.2741/1593. [DOI] [PubMed] [Google Scholar]
- 10.Johnson K., Polewski M., van Etten D., Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1 −/− mice. Arterioscler Thromb Vasc Biol. 2005;25:686–691. doi: 10.1161/01.ATV.0000154774.71187.f0. [DOI] [PubMed] [Google Scholar]
- 11.Nitschke Y., Hartmann S., Torsello G., Horstmann R., Seifarth H., Weissen-Plenz G. Expression of NPP1 is regulated during atheromatous plaque calcification. J Cell Mol Med. 2011;15:220–231. doi: 10.1111/j.1582-4934.2009.00988.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Terkeltaub R.A. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol. 2001;281:C1–C11. doi: 10.1152/ajpcell.2001.281.1.C1. [DOI] [PubMed] [Google Scholar]
- 13.Frittitta L., Youngren J., Vigneri R., Maddux B.A., Trischitta V., Goldfine I.D. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia. 1996;39:1190–1195. doi: 10.1007/BF02658505. [DOI] [PubMed] [Google Scholar]
- 14.Maddux B.A., Sbraccia P., Kumakura S., Sasson S., Youngren J., Fisher A. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature. 1995;373:448–451. doi: 10.1038/373448a0. [DOI] [PubMed] [Google Scholar]
- 15.Meyre D., Bouatia-Naji N., Tounian A., Samson C., Lecoeur C., Vatin V. Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes. Nat Genet. 2005;37:863–867. doi: 10.1038/ng1604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Nitschke Y., Baujat G., Botschen U., Wittkampf T., du Moulin M., Stella J. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet. 2012;90:25–39. doi: 10.1016/j.ajhg.2011.11.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Okawa A., Nakamura I., Goto S., Moriya H., Nakamura Y., Ikegawa S. Mutation in NPPs in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998;19:271–273. doi: 10.1038/956. [DOI] [PubMed] [Google Scholar]
- 18.Mackenzie N.C., Huesa C., Rutsch F., MacRae V.E. New insights into NPP1 function: lessons from clinical and animal studies. Bone. 2012;51:961–968. doi: 10.1016/j.bone.2012.07.014. [DOI] [PubMed] [Google Scholar]
- 19.Johnson K., Goding J., van Etten D., Sali A., Hu S.I., Farley D. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003;18:994–1004. doi: 10.1359/jbmr.2003.18.6.994. [DOI] [PubMed] [Google Scholar]
- 20.Mackenzie N.C., Zhu D., Milne E.M., van 't Hof R., Martin A., Darryl Q.L. Altered bone development and an increase in FGF-23 expression in Enpp1(−/−) mice. PLoS One. 2012;7:e32177. doi: 10.1371/journal.pone.0032177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Zhu D., Mackenzie N.C., Millan J.L., Farquharson C., MacRae V.E. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One. 2011;6:e19595. doi: 10.1371/journal.pone.0019595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Jande S.S., Belanger L.F. The life cycle of the osteocyte. Clin Orthop Relat Res. 1973:281–305. doi: 10.1097/00003086-197307000-00035. [DOI] [PubMed] [Google Scholar]
- 23.Arnett T.R. Osteocytes: regulating the mineral reserves? J Bone Miner Res. 2013;28:2433–2435. doi: 10.1002/jbmr.2119. [DOI] [PubMed] [Google Scholar]
- 24.Bonewald L.F. The amazing osteocyte. J Bone Miner Res. 2011;26:229–238. doi: 10.1002/jbmr.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Carpentier V.T., Wong J., Yeap Y., Gan C., Sutton-Smith P., Badiei A. Increased proportion of hypermineralized osteocyte lacunae in osteoporotic and osteoarthritic human trabecular bone: implications for bone remodeling. Bone. 2012;50:688–694. doi: 10.1016/j.bone.2011.11.021. [DOI] [PubMed] [Google Scholar]
- 26.Vaingankar S.M., Fitzpatrick T.A., Johnson K., Goding J.W., Maurice M., Terkeltaub R. Subcellular targeting and function of osteoblast nucleotide pyrophosphatase phosphodiesterase 1. Am J Physiol Cell Physiol. 2004;286:1177–1187. doi: 10.1152/ajpcell.00320.2003. [DOI] [PubMed] [Google Scholar]
- 27.Anderson H.C., Harmey D., Camacho N.P., Garimella R., Sipe J.B., Tague S. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol. 2005;166:1711–1720. doi: 10.1016/S0002-9440(10)62481-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Nam H.K., Liu J., Li Y., Kragor A., Hatch N.E. Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) protein regulates osteoblast differentiation. J Biol Chem. 2011;286:39059–39071. doi: 10.1074/jbc.M111.221689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Sali A., Favaloro J.M., Terkeltaub R., Goding J.W. In: Ecto-ATPases and related ectonucleotides. Vanduffe L., Lemmens R., editors. Shaker Publishing BV; Mastricht, the Netherlands: 1999. Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cell membrane glycoprotein (PC-1) produces abnormal calcification of the periarticular tissues; pp. 267–282. [Google Scholar]
- 30.Stern A.R., Stern M.M., Van Dyke M.E., Jahn K., Prideaux M., Bonewald L.F. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. Biotechniques. 2012;52:361–373. doi: 10.2144/0000113876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Orriss I.R., Hajjawi M.O.R., Huesa C., MacRae V.E., Arnett T.R. Optimisation of the differing conditions required for bone formation in vitro by primary osteoblasts from mice and rats. Int J Mol Med. 2014;34:1201–1208. doi: 10.3892/ijmm.2014.1926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45. doi: 10.1093/nar/29.9.e45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hernandez P., Whitty C., Wardale J.R., Henson F.M. New insights into the location and form of sclerostin. Biochem Biophys Res Commun. 2014;446:1108–1113. doi: 10.1016/j.bbrc.2014.03.079. [DOI] [PubMed] [Google Scholar]
- 34.Orriss I.R., Knight G.E., Utting J.C., Taylor S.E., Burnstock G., Arnett T.R. Hypoxia stimulates vesicular ATP release from rat osteoblasts. J Cell Physiol. 2009;220:155–162. doi: 10.1002/jcp.21745. [DOI] [PubMed] [Google Scholar]
- 35.Orriss I.R., Arnett T.R. Rodent osteoclast cultures. Methods Mol Biol. 2012;816:103–117. doi: 10.1007/978-1-61779-415-5_8. [DOI] [PubMed] [Google Scholar]
- 36.Arnett T.R., Dempster D.W. Effect of pH on bone resorption by rat osteoclasts in vitro. Endocrinology. 1986;119:119–124. doi: 10.1210/endo-119-1-119. [DOI] [PubMed] [Google Scholar]
- 37.Arnett T.R., Gibbons D.C., Utting J.C., Orriss I.R., Hoebertz A., Rosendaal M. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol. 2003;196:2–8. doi: 10.1002/jcp.10321. [DOI] [PubMed] [Google Scholar]
- 38.Hoebertz A., Arnett T.R. Isolated osteoclast cultures. Methods Mol Med. 2003;80:53–64. doi: 10.1385/1-59259-366-6:53. [DOI] [PubMed] [Google Scholar]
- 39.Razzell W.E., Khorana H.G. Studies on polynucleotides. III. Enzymic degradation; substrate specificity and properties of snake venom phosphodiesterase. J Biol Chem. 1959;234:2105–2113. [PubMed] [Google Scholar]
- 40.Dunn O.J. Multiple comparisons among means. J Am Stat Assoc. 1961;56:52–64. [Google Scholar]
- 41.Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50:1096–1121. [Google Scholar]
- 42.Busse B., Djonic D., Milovanovic P., Hahn M., Puschel K., Ritchie R.O. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell. 2010;9:1065–1075. doi: 10.1111/j.1474-9726.2010.00633.x. [DOI] [PubMed] [Google Scholar]
- 43.Genetos D.C., Kephart C.J., Zhang Y., Yellowley C.E., Donahue H.J. Oscillating fluid flow activation of gap junction hemichannels induces ATP release from MLO-Y4 osteocytes. J Cell Physiol. 2007;212:207–214. doi: 10.1002/jcp.21021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Kringelbach T.M., Aslan D., Novak I., Schwarz P., Jorgensen N.R. UTP-induced ATP release is a fine-tuned signalling pathway in osteocytes. Purinergic Signal. 2013;10:337–347. doi: 10.1007/s11302-013-9404-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Villa-Bellosta R., Wang X., Millan J.L., Dubyak G.R., O'Neill W.C. Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2011;301:H61–H68. doi: 10.1152/ajpheart.01020.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Arnett T.R. Acidosis, hypoxia and bone. Arch Biochem Biophys. 2010;503:103–109. doi: 10.1016/j.abb.2010.07.021. [DOI] [PubMed] [Google Scholar]
- 47.Brandao-Burch A., Utting J.C., Orriss I.R., Arnett T.R. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int. 2005;77:167–174. doi: 10.1007/s00223-004-0285-8. [DOI] [PubMed] [Google Scholar]
- 48.Utting J.C., Robins S.P., Brandao-Burch A., Orriss I.R., Behar J., Arnett T.R. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res. 2006;312:1693–1702. doi: 10.1016/j.yexcr.2006.02.007. [DOI] [PubMed] [Google Scholar]
- 49.Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–192. doi: 10.1038/nm.3074. [DOI] [PubMed] [Google Scholar]
- 50.Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283:5866–5875. doi: 10.1074/jbc.M705092200. [DOI] [PubMed] [Google Scholar]
- 51.Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24:1651–1661. doi: 10.1359/jbmr.090411. [DOI] [PubMed] [Google Scholar]
- 52.Macias B.R., Aspenberg P., Agholme F. Paradoxical Sost gene expression response to mechanical unloading in metaphyseal bone. Bone. 2013;53:515–519. doi: 10.1016/j.bone.2013.01.018. [DOI] [PubMed] [Google Scholar]
- 53.Spatz J.M., Fields E.E., Yu E.W., Divieti P.P., Bouxsein M.L., Sibonga J.D. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012;97:1736–1740. doi: 10.1210/jc.2012-1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Spatz J.M., Ellman R., Cloutier A.M., Louis L., van Vliet M., Suva L.J. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013;28:865–874. doi: 10.1002/jbmr.1807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Ryan Z.C., Ketha H., McNulty M.S., McGee-Lawrence M., Craig T.A., Grande J.P. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A. 2013;110:6199–6204. doi: 10.1073/pnas.1221255110. [DOI] [PMC free article] [PubMed] [Google Scholar]